1
The study was a randomized, double-blind, cross-over trial preceded by a placebo run-in period.
2
The study was of double-blind, parallel design, with a placebo run-in period of 15 days.
3
After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized.
4
Participants underwent a 4-week run-in period to standardize dialysis prescription and dry weight on the basis of clinical examination.
5
Ambulatory BP monitoring was obtained at the end of a 4-week placebo run-in period and during the last week of treatment.
6
All patients received pranlukast (225 mg twice daily) for 4 weeks after a 2-week run-in period.
7
Twenty-four-hour ambulatory BP (ABP) was measured at the end of a 2-week run-in period (baseline) and after each 4-week intervention period.
8
The study design was a double blind, randomized, placebo-controlled intervention study, with a 4-week run-in period, followed by an 8-week test beverage ingestion period.
9
Methods: In study 1, after a 1-week placebo run-in period, blood pressure and the pulse rate were measured every 2 h except at night.